Antibiotic susceptibility of cystic fibrosis lung microbiome members in a multispecies biofilm by Vandeplassche, Eva et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Antibiotic susceptibility of cystic fibrosis lung microbiome members in a multispecies
biofilm
Vandeplassche, Eva; Sass, Andrea; Ostyn, Lisa; Burmølle, Mette; Kragh, Kasper Nørskov;
Bjarnsholt, Thomas; Coenye, Tom; Crabbé, Aurélie
Published in:
Biofilm
DOI:
10.1016/j.bioflm.2020.100031
Publication date:
2020
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC-ND
Citation for published version (APA):
Vandeplassche, E., Sass, A., Ostyn, L., Burmølle, M., Kragh, K. N., Bjarnsholt, T., ... Crabbé, A. (2020).
Antibiotic susceptibility of cystic fibrosis lung microbiome members in a multispecies biofilm. Biofilm, 2, [100031].
https://doi.org/10.1016/j.bioflm.2020.100031
Download date: 10. sep.. 2020
Biofilm 2 (2020) 100031Contents lists available at ScienceDirect
Biofilm
journal homepage: www.elsevier.com/locate/bioflmAntibiotic susceptibility of cystic fibrosis lung microbiome members in a
multispecies biofilm
Eva Vandeplassche a, Andrea Sass a, Lisa Ostyn a, Mette Burmølle b, Kasper Nørskov Kragh c,
Thomas Bjarnsholt c,d, Tom Coenye a, Aurelie Crabbe a,*
a Laboratory of Pharmaceutical Microbiology, Ghent University, Belgium
b Department of Microbiology, University of Copenhagen, Denmark
c Costerton Biofilm Center, Department of Immunology and Microbiology, University of Copenhagen, Denmark
d Department of Clinical Microbiology, Copenhagen University Hospital, DenmarkA R T I C L E I N F O
Keywords:
Multispecies biofilms
Antibiotics
Cystic fibrosis
Microbial diversity
Microbiota* Corresponding author.
E-mail address: aurelie.crabbe@ugent.be (A. Cra
https://doi.org/10.1016/j.bioflm.2020.100031
Received 17 January 2020; Received in revised for
Available online 13 June 2020
2590-2075/© 2020 Published by Elsevier B.V. ThisA B S T R A C T
The lungs of cystic fibrosis (CF) patients are often chronically colonized by multiple microbial species that can
form biofilms, including the major CF pathogen Pseudomonas aeruginosa. Herewith, lower microbial diversity in
CF airways is typically associated with worse health outcomes. In an attempt to treat CF lung infections patients
are frequently exposed to antibiotics, which may affect microbial diversity. This study aimed at understanding if
common antibiotics that target P. aeruginosa influence microbial diversity. To this end, a microaerophilic
multispecies biofilm model of frequently co-isolated members of the CF lung microbiome (Pseudomonas aerugi-
nosa, Staphylococcus aureus, Streptococcus anginosus, Achromobacter xylosoxidans, Rothia mucilaginosa, and Gemella
haemolysans) was exposed to antipseudomonal antibiotics. We found that antibiotics that affected several
dominant species (i.e. ceftazidime, tobramycin) resulted in higher species evenness compared to colistin, which is
only active against P. aeruginosa. Furthermore, susceptibility of individual species in the multispecies biofilm
following antibiotic treatment was compared to that of the respective single-species biofilms, showing no dif-
ferences. Adding three anaerobic species (Prevotella melaninogenica, Veillonella parvula, and Fusobacterium nucle-
atum) to the multispecies biofilm did not influence antibiotic susceptibility. In conclusion, our study demonstrates
antibiotic-dependent effects on microbial community diversity of multispecies biofilms comprised of CF micro-
biome members.Introduction
The lungs of cystic fibrosis (CF) patients are highly susceptible to
bacterial infections [1,2]. Additionally, bacteria in the CF airways mostly
persist as biofilm structures that are more tolerant to antimicrobial agents
which leads to recurrent and chronic infections [3]. Subsequently, a
repeated cycle of infection, hyperinflammation, and airway obstruction
results in a decline of lung function [2,4]. One of the major pathogens
associated with pulmonary deterioration in the CF lung is Pseudomonas
aeruginosa [5]. Yet, this bacterium is not the sole colonizer of the CF
airways and it is now clear that CF lungs contain a wide collection of
microorganisms, designated as the CF lung microbiome [6–9].
Besides the well-studied CF pathogens P. aeruginosa, Staphylococcus
aureus, Haemophilus influenzae, and Burkholderia cenocepacia, the CF lung
microbiome may contain other potentially pathogenic species, such asbbe).
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is an open access article under tAchromobacter xylosoxidans, members of the Streptococcus milleri group,
Ralstonia spp., Pandorea spp., Stenotrophomonas maltophilia, and Myco-
bacterium spp [7,8,10,11]. Furthermore, oral bacteria also find their way
into the CF airways and become part of the bacterial community, with
Rothia mucilaginosa, Gemella haemolysans and several anaerobic species
being most frequently isolated [11–14]. Anaerobes, such as Prevotella
spp, Veillonella spp., and Fusobacterium spp., are increasingly being
recognized as more than innocent bystanders given the growing evidence
provided by culture-(in)dependent methods that they can persist in CF
patients’ lungs [13,15,16]. The complex bacterial airway community
evolves over a patient’s lifetime and is influenced by external factors such
as antibiotic treatment [17–20]. In older CF patients the sputum micro-
biome typically becomes less diverse which is associatedwith a decline in
lung function and thus worse health outcomes [17,18].
It has been hypothesized that the bacterial species present in the CFe 2020
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Fig. 2. Biomass of single-, dual-, and multispecies biofilms. Biomass was
determined by crystal violet staining. Pa: P. aeruginosa, Sa: S. aureus, Sag:
S. anginosus, Ax: A. xylosoxidans, Rm: R. mucilaginosa, Gh: G. haemolysans, Multi:
multispecies biofilm of all six bacterial species. All graphs show means; error
bars indicate standard deviations, n  3, *p  0.05.
E. Vandeplassche et al. Biofilm 2 (2020) 100031lung microbiome can influence each other when in close proximity
[21–24]. In vitro experiments using polymicrobial communities, typically
comprised of two to three microbiome members, have provided valuable
insights in the influence of interspecies interactions on (biofilm) growth,
antibiotic susceptibility, and expression of virulence factors by CF path-
ogens [25–28]. However, the antibiotic susceptibility of individual bac-
teria in polymicrobial communities that reflect the microbial diversity of
CF lungs has been poorly investigated.
In the present study we used our previously developed multispecies
biofilm community model comprised of six commonly co-isolated CF
microbiome members (i.e. P. aeruginosa, S. aureus, A. xylosoxidans,
Streptococcus anginosus, R. mucilaginosa, G. haemolysans [29]) to study the
influence of different antibiotic treatments on microbial community di-
versity. First, we evaluated biofilm formation of these strains in the
multispecies biofilm model. Subsequently, the effect on community di-
versity of four antibiotics commonly used to treat P. aeruginosa in the CF
lung was investigated. In addition, antibiotic susceptibility of individual
CF microbiome members grown as multispecies biofilms was compared
with that of single-species biofilms. Finally, in order to determine the
potential role of anaerobes, three anaerobic species (Prevotella melani-
nogenica, Fusobacterium nucleatum, Veillonella parvula) were added to the
multispecies community and antibiotic susceptibility of all species in the
multispecies biofilm model was determined.
Results & discussion
Biofilm formation of the microaerophilic multispecies consortium
First, we evaluated whether biofilm formation was different in a
single versus multispecies community. All aerobic strains formed bio-
films of 5–8 log CFU/mL in the single-species biofilms as well as in the
multispecies biofilm containing all six strains together (Fig. 1). In the
multispecies biofilm P. aeruginosa, S. anginosus, and A. xylosoxidans grew
to the same density as in their respective single-species biofilms. For
S. aureus, R. mucilaginosa, and G. haemolysans the number of CFU was
significantly lower in the multispecies biofilm than in the respective
single-species biofilms (p-values: P. aeruginosa 0.196, S. aureus 0.001,
S. anginosus 0.357, A. xylosoxidans 0.278, R. mucilaginosa 0.001,
G. haemolysans 0.013). Next, we evaluated the growth of all bacterial
species under the same experimental conditions as used to culture single-
and multispecies biofilms (i.e. BHI þ LYS medium, microaerophilic
conditions) (Fig. S1). While we observed differences in the maximal
optical density reached, all species grew to stationary phase in the 48h
time frame of the experiment, with the exception of A. xylosoxidans that
reached exponential phase at the 48h time point. The slower growth of
A. xylosoxidans could explain less biofilm formation both in single and
multispecies biofilms compared to other species, such as P. aeruginosa.2Then, we investigated the lower density of S. aureus, R. mucilaginosa,
and G. haemolysans in a multi-versus single-species biofilm further. The
inhibitory effect of P. aeruginosa on S. aureus in vitro growth has been
described [30,31] and to determine whether the lower numbers of
S. aureus, R. mucilaginosa and G. haemolysans in the multispecies biofilm
could be due to the presence of P. aeruginosa.
Next, we analysed the influence of growth in a multispecies com-
munity on biofilm biomass. No significant difference was observed be-
tween single- and multispecies biofilms in terms of total biomass
production as assessed by crystal violet staining (Fig. 2). Hence, the
previously described increased biomass production of P. aeruginosa and
S. aureus mixed biofilms compared to single species biofilms was not
observed in our multispecies biofilm model [23]. To determine whether
differences between our study and the previous report were due to dif-
ferences in experimental set-up (such as culture media, strains, oxygen
levels) or community complexity we evaluated the biofilm mass of
dual-species biofilms of P. aeruginosa and each individual species. We
found a significantly higher biomass in dual-species biofilms of
P. aeruginosa and S. aureus compared to that of single-cultures (Fig. 2)
(p-values: P. aeruginosa 0.029, S. aureus 0.049). These data suggest that
other species in the multispecies biofilm can counteract increases in
biomass caused by dual-species interactions.
Taken together, these data indicate that the formation of biofilms by
the six selected CF microbiome members in a multispecies biofilm occurs
to a lower extent than single-species biofilms for some bacteria. The
multispecies biofilm model was subsequently applied to investigate the
effect of different antibiotics on community richness and evenness.Fig. 1. Log CFU/mL of single-, dual-, and multi-
species biofilms. Log CFU/mL was determined by
plating on selective media. Pa: P. aeruginosa, Sa:
S. aureus, Sag: S. anginosus, Ax: A. xylosoxidans, Rm:
R. mucilaginosa, Gh: G. haemolysans, Multi: multispe-
cies biofilm of all six bacterial species. All graphs
show means and error bars indicate standard de-
viations, n  3, *p  0.05 (compared to single-species
biofilm). dual-species biofilms of P. aeruginosa and
each individual microbiome member were cultured
(Fig. 1). In dual-species biofilms S. aureus, R. mucila-
ginosa and G. haemolysans also grew to densities
significantly (p-values: S. aureus 0.007,
R. mucilaginosa 0.009, G. haemolysans < 0.001) lower
than in the single-species biofilm which were com-
parable to what was observed in the multispecies
biofilm. This suggests that the presence of
P. aeruginosa was responsible for the observed inhib-
itory effect.
E. Vandeplassche et al. Biofilm 2 (2020) 100031Effect of antibiotic treatment on the diversity of a multispecies biofilm of CF
lung microbiome members
The effect of different antibiotics used to treat P. aeruginosa infections
in CF patients (i.e. ceftazidime, ciprofloxacin, colistin, tobramycin) was
evaluated on the diversity of the multispecies biofilms (Fig. 3). In this
study we focused on the remaining biofilm following antibiotic treat-
ment, as the biofilm phenotype in the mucus of CF patients is believed to
be the main contributor to chronic lung infections and high antibiotic
tolerance [3,32,33]. We observed that all species were present before and
after antibiotic treatment, hence species richness was equal for all
multispecies biofilms. Species evenness is based on the relative amounts
of each species present and was calculated using the Pielou’s evenness
index. For the multispecies biofilms the following Pielou’s indices were
calculated: untreated 0.439; ceftazidime 0.694; ciprofloxacin 0.534;
colistin 0.160; tobramycin 0.537. Antibiotics that affected several
dominant species resulted in a higher species evenness compared to the
untreated control. This includes ceftazidime which affected the dominant
pathogens P. aeruginosa, S. aureus and S. anginosus, and tobramycin which
affected P. aeruginosa and S. aureus. In contrast, colistin, an antibiotic that
was only active against P. aeruginosa, led to lower community evenness.
The reason for the lower community evenness with colistin treatment is
that another pathogen, i.e. S. anginosus, now dominates the community.
Prior to antibiotic treatment, both P. aeruginosa and S. anginosuswere the
dominant species in the multispecies biofilms (Fig. 3B), a phenotype
which is often observed in CF patients [34,35]. Treatment targeting
P. aeruginosa did not affect S. anginosus absolute abundance (Fig. 3A) but
strongly influenced the relative abundance of this microorganism
(Fig. 3B). In contrast, antibiotics that eradicated both dominant patho-
gens S. anginosus and P. aeruginosa (ceftazidime and tobramycin)3improved community diversity.
While community composition is reported to be altered (transiently)
by acute antibiotic therapy in CF patients [14,36–40], the effect of spe-
cific antibiotics on microbial diversity in vitro or in vivo is mostly unex-
plored. Hence, in vitro multispecies biofilm models can serve as tools to
evaluate the effect of (new) narrow/broad-spectrum antimicrobial
treatments on community diversity, even though in vivo validation would
be needed.Antibiotic susceptibility of CF microbial community members in a multi- and
single species biofilm model
Next, we evaluated whether antibiotic susceptibility of CF micro-
biomemembers was different when grown in a single-versus multispecies
biofilm. To this end, established single- or multispecies biofilms were
exposed to four different antibiotics (i.e. ceftazidime, ciprofloxacin,
colistin, tobramycin) and the eradication after 24h treatment was
determined. For the multispecies biofilms, the data of Fig. 3 was con-
verted to biofilm eradication. No significant differences were observed
between bacterial killing in single- and multispecies biofilms (Fig. 4).
However, in previous studies (with less complex communities) it has
been shown that community composition does influence killing [24,
41–44]. Whether the difference between previously-obtained data and
results from the present study are due to the specific taxa investigated,
the antibiotics (and/or their concentration) tested, the environmental
conditions and/or are related to the increase in community complexity of
the multispecies biofilm compared to previous studies, remains to be
determined. In addition, the isolation source of the different species and
their co-evolution might also influence the experimental outcome [45]. It
should be noted that in our study BHI medium supplemented with lysedFig. 3. Comparison of species diversity in (un)treated
multispecies biofilms: (A) Log CFU/mL values and (B)
relative abundances. Species richness and evenness
were assessed in four treated multispecies biofilms
versus an untreated control biofilm. UNTR: untreated,
CEF: 2000 μg/mL ceftazidime, CIP: 0.5 μg/mL, COL:
100 μg/mL colistin, TOB: 100 μg/mL tobramycin. Pa:
P. aeruginosa, Sa: S. aureus, Sag: S. anginosus, Ax:
A. xylosoxidans, Rm: R. mucilaginosa, Gh:
G. haemolysans. Graphs show means and error bars
indicate standard deviations, n  3, *p  0.05 (treated
versus untreated).
Fig. 4. Log CFU/mL biofilm eradication of single-versus multispecies biofilms. Log CFU/mL determined by plating on selective media for (A) P. aeruginosa, (B)
S. aureus, (C) S. anginosus, (D) A. xylosoxidans, (E) R. mucilaginosa, and (F) G. haemolysans. CEF: ceftazidime 2000 μg/mL, CIP: ciprofloxacin 0.5 μg/mL, COL: colistin
100 μg/mL, TOB: tobramycin 100 μg/mL. All graphs show means and error bars indicate standard deviations, n  3.
E. Vandeplassche et al. Biofilm 2 (2020) 100031blood was used for generating multispecies biofilms, which is not
reflective of the CF nutritional environment. While this is a limitation of
our study, accurate quantification of multispecies biofilms using plating
and crystal violet assays is challenging in viscous synthetic sputum
media, especially in a high through-put setting. Nevertheless, evaluation
of multispecies biofilm formation and their susceptibility to antibiotics in
more relevant media, such as synthetic cystic fibrosis medium 2 (SCFM2)
[46] might influence the outcomes and remains to be evaluated.Fig. 5. Single-species biofilm formation (log CFU/mL) of 3 anaerobic
strains in microaerophilic and anaerobic conditions. PRE: P. melaninogenica.
VEIL: V. parvula. FUSO: F. nucleatum. Graphs show means and error bars indicate
standard deviations, n  3.Effect of anaerobic species on antibiotic susceptibility of CF microbiome
members
CF lungs are often colonized by anaerobic species, and their role in
lung disease remains contradictory [13,47,48]. Therefore, we investi-
gated if common anaerobic species of the CF lung microbiome influence
the biofilm formation and antibiotic susceptibility of multispecies bio-
films. To this end, the six CF strains were grown as biofilms in the
presence of P. melaninogenica, V. parvula, F. nucleatum, or a combination
of all three, and the biofilm formation and antibiotic susceptibility of
each community member was determined as described before. First, to
ensure that P. melaninogenica, V. parvula, and F. nucleatum could form
biofilms in microaerophilic and anaerobic conditions, these species were
grown as mono-culture biofilms (Fig. 5). We found that all three strains
were able to form biofilms containing at least 7 log CFU/mL in anaerobic4as well as microaerophilic conditions. This finding allowed us to add the
anaerobic strains to the existing microaerophilic multispecies biofilm
community model using the same experimental conditions as previously
described.
Next, we assessed whether the anaerobic strains were present and
grew during 48h multispecies biofilm development using qPCR analysis.
Table 1
Cq-values for P. melaninogenica, V. parvula, and F. nucleatum (and negative controls) in the multispecies biofilm (obtained via qPCR) and the estimated log CFU/mL
(based on Cq-values).
Species name Mean Cq-value StDev Negative control Estimated log CFU/mL
P. melaninogenica 20.09 1.13 37.59 6.51
V. parvula 14.42 2.26 No signal 7.16
F. nucleatum 14.62 0.85 No signal 6.64
StDev: standard deviation. No signal ¼ Cq-value > 40.00.
E. Vandeplassche et al. Biofilm 2 (2020) 100031An estimation of the abundance of each anaerobic strain was made based
on a standard curve of DNA concentration vs. Cq-values. At the start of the
multispecies biofilm experiment, 2.5  106 CFU/mL of each strain was
added (approx. 6.40 log CFU/mL). After 48h biofilm formation the
calculated log CFU/mL values for all anaerobic strains in the multispecies
biofilm were similar to (for P. melaninogenica and F. nucleatum) or higher
than (for V. parvula) this inoculum (Table 1). These data indicate that all
anaerobic strains were present, and that for V. parvula growth occurred,
over the 48h incubation period. Nevertheless, we cannot exclude that a
part of the detected DNA was derived from non-viable bacteria or
extracellular DNA, leading to a possible overestimation of the estimated
log CFU/mL in the multispecies biofilm.
Next, biofilm formation and antibiotic susceptibility of all six strains
was evaluated in the multispecies biofilms in the presence of
P. melaninogenica, V. parvula, or F. nucleatum, or a combination of all
three. None of the aerobic or microaerophilic biofilm community mem-
bers were influenced by the presence of anaerobic strains (Figs. 6 and 7).
Anaerobic species have increasingly become the subject of research
with the discovery that they are abundant in the CF lungmicrobiome [13,
15,16] and may influence other members of the microbial community
[13]. For example, Sherrard et al [49]. showed that Prevotella spp. can
secrete extended-spectrum β-lactamases, hereby protecting P. aeruginosa
from the antimicrobial action of ceftazidime. Additionally, Luppens et al
[50]. found that in a dual-species biofilm of V. parvula with Streptococcus
mutans the latter showed increased survival after various antimicrobial
treatments (amine chloride, zinc chloride, erythromycin, or hydrogen
peroxide). In the context of dental plaque co-cultivation of Veillonella spp.
and Streptococcus spp., and S. mutans and F. nucleatum led to specific
co-aggregation, resulting in facilitated early biofilm formation [51,52].
Enhancing the complexity of in vitro multispecies communities,
hereby increasing physiological relevance, may thus provide a different
experimental outcome in comparison to co-cultures of two or three
bacterial species [28]. Although community complexity in the present
study is enhanced compared to previous reports, the multispecies biofilm
model is still composed of a limited number of species and contains
multiple pathogens. Hence, the effect of antibiotic treatment on the di-
versity of a richer and more diverse bacterial community may have a
different experimental outcome. Furthermore, as mentioned earlier dif-
ferences in experimental set-up (culture medium, strains, antibiotic
concentrations, oxygen levels) should also be considered. Finally, our
experimental approach that studied the response of the community as a
whole does not capture spatial heterogeneity of the biofilm [53], where
local interspecies interactions could potentially lead to effects on anti-
biotic susceptibility.
In conclusion, exposure of multispecies biofilms to different antibi-
otics that are commonly used to treat P. aeruginosa lung infections in CF
patients revealed antibiotic-dependent effects on microbial community
evenness. We observed that antibiotics that simultaneously targeted
other dominant pathogens besides P. aeruginosa led to a community with
higher evenness as compared to antibiotics that were only active against
P. aeruginosa. In addition, the antibiotic susceptibility of individual
members in the CF biofilm community was comparable to that of single
species biofilms, indicating that the complex community did not influ-
ence antibiotic efficacy under our experimental conditions.
This study highlights that controlled in vitro multispecies models can
provide information on the influence of external disturbances, such as5antibiotic treatment, on microbiome composition and diversity. Insights
from these types of model platforms may be useful to fine-tune antimi-
crobial treatment strategies in ways that restore and/or limit effects on
microbial diversity while targeting key CF pathogens.
Materials and methods
Bacterial strains and culturing conditions
Strains used in this study are listed in Table 2, and were first cultured
from 80 C glycerol stocks onto suitable solid media. Liquid cultures
were then grown until stationary phase at 37 Cwhile shaking at 250 rpm
in BHI broth, with supplementation of 2.5% lysed blood (Biotrading;
protocol for lysed horse blood according to EUCAST) [54] (BHI þ LYS)
for the anaerobic strains (Table 2). S. anginosus and G. haemolysans cul-
tures were incubated in microaerophilic conditions (5%O2,15% CO2;
CampyGen Compact system, Thermo Fisher Scientific, USA) while
P. melaninogenica, V. parvula, and F. nucleatum cultures were incubated in
anaerobic conditions (AnaeroGen Compact system, Thermo Fisher
Scientific).
Growth curves
Bacterial liquid cultures were grown to stationary phase as described
above, and diluted to 5  107 CFU/mL (based on OD590nm) in BHI þ LYS
medium. Diluted cultures were transferred to 96-well plates (100 μL/
well) and incubated statically for 48 h at 37 C in an EnVision Multilabel
Plate Reader (PerkinElmer, USA), and OD590nm was measured every 30
min. To generate microaerophilic conditions, the outer wells of the plate
were filled with ascorbic acid from CampyGen Compact System (Ther-
mofisher Scientific, USA), and the plate was sealed with silicone.
Formation of single- and multispecies biofilms
Biofilms were grown in a PVC flat-bottomed 96-well microtiter plate
(Thermo Fisher) as described previously in BHI þ LYS medium [29].
While the composition of this medium does not reflect the CF nutritional
environment, it was used since all selected species survived and/or grew
in this medium for the duration of the experiment, and allowed selective
quantification of the biofilm fraction and biomass using conventional
protocols. Briefly, stationary phase liquid cultures were diluted in BHI þ
LYS to approx. 5 107 CFU/mL (based on OD590nm). In all conditions, an
equal number of cells per strain (2.5  106 CFU, i.e. 50 μL) was inocu-
lated while the final volume in each well was 100 μL, which was obtained
by concentrating the samples via centrifugation. All 96-well plates were
incubated in a microaerophilic environment (5% O2, 15% CO2;
CampyGen Compact system), thereby mimicking the low oxygen condi-
tions in the CF lung [56,57], at 37 C for 24 h.
Effect of antibiotic exposure on single- and multispecies biofilms
24 h old biofilms were exposed to antibiotics for an additional 24 h as
described previously [29], where after the abundance of each species was
determined by plating on selective media [29]. Briefly, the biofilms were
first rinsed with physiological saline solution (PS; 0.9% [w/v] NaCl in
milliQ water). Subsequently, 100 μL of medium (BHIþ LYS) or 100 μL of
Fig. 6. Biofilm formation (log CFU/mL) of multispecies biofilms in the presence of anaerobic species. MULTI: multispecies biofilm of six aerobic and
microaerophilic strains. Pa: P. aeruginosa, Sa: S. aureus, Sag: S. anginosus, Ax: A. xylosoxidans, Rm: R. mucilaginosa, Gh: G. haemolysans. PRE: P. melaninogenica, VEIL:
V. parvula, FUSO: F. nucleatum. ALL: P. melaninogenica, V. parvula, and F. nucleatum. Graphs show means and error bars indicate standard deviations, n  3.
Fig. 7. Log CFU/mL biofilm eradication of (A) P. aeruginosa, (B) S. aureus, (C) S. anginosus, (D) A. xylosoxidans, (E) R. mucilaginosa, and (F) G. haemolysans in the
presence of anaerobic strains, after treatment with ceftazidime (CEF), ciprofloxacin (CIP), colistin (COL), or tobramycin (TOB). MULTI: multispecies biofilm of six
aerobic and microaerophilic strains. PRE: P. melaninogenica. VEIL: V. parvula. FUSO: F. nucleatum. ALL: P. melaninogenica, V. parvula, and F. nucleatum. All graphs show
means and error bars indicate standard deviations, n  3.
E. Vandeplassche et al. Biofilm 2 (2020) 100031antibiotic solution in the same medium was added to the untreated
(control) and treated biofilms, respectively. Four antibiotics from four
major antibiotic classes frequently used to treat P. aeruginosa in CF were
selected: ceftazidime (2000 μg/mL, 125x MIC P. aeruginosa),6ciprofloxacin (0.5 μg/mL, 2xMIC P. aeruginosa), colistin (100 μg/mL, 25x
MIC P. aeruginosa), and tobramycin (100 μg/mL, 100xMIC P. aeruginosa).
Antibiotic concentrations were chosen to obtain P. aeruginosa killing of
around 2–3 log CFU/mL, based on optimisation experiments. MICs of
Table 2
Overview of strains and culturing conditions used in this study.
Species name Strain
number
Source Liquid
culture
medium
Solid
medium
Pseudomonas
aeruginosa
AA2 ¼
LMG27630
CF lung (early
infection)
BHI LB
Staphylococcus
aureus
SP123 Sputum
(Belgium) [55]
BHI LB
Streptococcus
anginosus
LMG14696 Respiratory tract BHI BHI
Achromobacter
xylosoxidans
LMG26680 Sputum CF
patient
(Belgium)
BHI NA
Rothia
mucilaginosa
DSM20746 Throat BHI NA
Gemella
haemolysans
LMG18984 Sputum BHI CBA
Prevotella
melaninogenica
DSM7089 Sputum BHI þ LYS CBA
Veillonella parvula DSM2007 Mouth BHI þ LYS CBA
Fusobacterium
nucleatum
DSM19507 Periodontal
pocket
BHI þ LYS CBA
BHI: Brain Heart Infusion broth/agar; LYS: lysed horse blood; LB: Luria Bertani
agar; NA: Nutrient agar; CBA: Columbia Blood Agar (Columbia agar base þ 5%
sheep blood).
E. Vandeplassche et al. Biofilm 2 (2020) 100031these antibiotics for P. aeruginosa, S. aureus, S. anginosus, A. xylosoxidans,
R. mucilaginosa, and G. haemolysans were determined using EUCAST
guidelines [54], and are presented in Table S1. All biofilms were incu-
bated under microaerophilic conditions at 37 C for 24 h. Subsequently,
biofilms were rinsed with physiological saline to remove planktonic cells
before quantification. To quantify the number of colony forming units
(CFU) of P. aeruginosa, S. aureus, S. anginosus, A. xylosoxidans,
R. mucilaginosa, and G. haemolysans, biofilms were homogenized by two
rounds of vortexing (900 rpm, 5 min) and sonication (5 min; Branson
Ultrasonic bath, Hach Company, USA), and plated on six selective media,
as described previously [29]. To investigate antibiotic susceptibility of
biofilms, the log CFU/mL value for the treated single- or multispecies
biofilm was subtracted from the log CFU/mL value from the untreated
single- or multispecies biofilms. This resulted in a ‘log CFU/mL eradi-
cation’ value. Finally, biomass of biofilms was quantified by crystal violet
staining as described elsewhere [58].
Pielou’s evenness index calculation
Diversity indices represent a combination of richness and evenness
components. The richness of a community is based on the number of
different species that are present, while the evenness shows how similar
the relative quantities of the species are [59]. Pielou’s evenness index (J0)
is based on the Shannon diversity index and is given by the following
formula:
J’ ¼ H’
H’max
(1)
where H0 is the Shannon diversity index [H ¼P - (Pi * ln Pi) (with Pi ¼
proportional abundance)], H’max ¼ ln(S) and S is the total number of
species. J0 has a value between 0 and 1; 0 being the most uneven and 1
the most even community [59,60].
DNA extraction from planktonic and biofilm cultures
For single-species planktonic cultures, 2 mL of stationary phase cul-
tures were centrifuged and the pellet resuspended in TE buffer (200 μL;
10 mM Tris-HCl pH 8; 1 mM EDTA pH 8). The resuspended pellet was
pre-treated with 20 mg/mL lysozyme (Sigma-Aldrich, USA) and 0.1 mg/
mL proteinase K (Sigma-Aldrich) at 37 C for 1 h. Then, 100 μL of this
suspension was added to ‘lysis tubes’ containing 500 μL acid-washed7glass beads (Sigma-Aldrich) and 500 μL lysis buffer (50 mM Tris-HCl
pH 8, 70 mM EDTA pH 8, 1% sodium dodecyl sulphate) supplemented
with 0.5 μg/mL pronase (Roche, Germany). After vortexing, the tubes
were incubated at 37 C for 1 h and then centrifuged (13,000 rpm).
Saturated ammonium acetate (200 μL) was added, the mixture was
vortexed again, and centrifuged for 2 min. Then, chloroform (600 μL)
was added, vortexed, and centrifuged for 5 min to separate the phases.
Afterwards, 400 μL of the top phase was transferred to a tube containing
1 mL of 100% ethanol. After mixing by inversion, this was centrifuged for
5 min. The supernatant was removed, the pellet washed with 70%
ethanol, and then air-dried. Resulting DNA was dissolved in low-EDTA-
TE buffer [10 mM Tris-HCl pH 8; 0.1 mM EDTA pH 8; 0.5 μg/mL
RNase A (Qiagen, Germany)]. DNA of multispecies biofilms was extrac-
ted using the PureLink Microbiome DNA extraction kit (Thermo Fisher
Scientific) according to the manufacturer’s instructions. DNA concen-
trations were measured using the BioDrop μLITE (Isogen Life Science,
The Netherlands).
Quantitative real-time PCR
To confirm the presence of P. melaninogenica, V. parvula, and
F. nucleatum in the multispecies biofilms, quantitative real-time PCR
(qPCR) (C1000 Touch Thermal Cycler, Bio-rad) was performed using
primers targeting the 16S rRNA gene (Table 3). Primers for V. parvula and
F. nucleatum were previously described [61]. For P. melaninogenica,
primers targeting the V1 and V2 hypervariable regions of the 16S rRNA
genes were designed using Primer3Web version 4.1.0 (http://primer3.ut
.ee/) using the following parameters: optimal primer size 20 (range: 18 to
27), optimal Tm 60 (range 57–63) and GC content from 20 to 80%.
Primers were then blasted against the genomes of all other eight species,
to rule out sequence complementarity. A common annealing temperature
(58 C) for all primers was determined via temperature gradient qPCR.
Each qPCR reaction (total volume of 20 μL) contained 1 μL salmon
sperm DNA (25 ng/μL; Sigma-Aldrich), 0.6 μL primer mix (Sigma-
Aldrich; 10 μM), 10 μL Perfecta SYBR Green Fast mix (Quanta bio, USA),
and 2 μL template DNA (25 ng/μL). Non-target salmon sperm DNA was
added to all samples to prevent sample loss from binding to (low-bind)
tubes.
Specificity of the primers was confirmed by PCR, followed by gel
electrophoresis, and by melting curve analysis. Amplification efficiency
(E) was determined using the following formula: E ¼ 10^(-1/slope) (with
slope being the slope of the dilution curve obtained with 10-fold di-
lutions), and correlations with equation y ¼ 4.08x þ 18.21 (R2 ¼
0.9994), y ¼ 3.78x þ 15.16 (R2 ¼ 0.9979), y ¼ 3.47x þ 15.51 (R2 ¼
0.9786) were obtained for P. melaninogenica, V. parvula and F. nucleatum,
respectively. qPCR reaction efficiency in the presence or absence of non-
target bacterial DNA was compared by composing a standard curve of
various target DNA concentrations (1/5 dilutions; 500–0.8 pg/μL) with
or without a DNA mix of all other species (P. aeruginosa, S. aureus,
S. anginosus, A. xylosoxidans, R. mucilaginosa, G. haemolysans, and the two
non-target anaerobes, with a total final concentration of 1 ng/μL in the
reaction), resulting in a standard curve of DNA concentration vs. Cq-
values (Supplementary Fig. S2). The slope and individual Cq-values for
each sample were not affected by the presence of microbiome members.
Finally, the Cq-value for each anaerobic strain in the multispecies biofilm
was determined (Table 3) and used to estimate the log CFU/mL of each of
the anaerobic strains in the multispecies biofilm (Table 3 & Supple-
mentary Fig. S3). This approach allowed to estimate the abundance of the
anaerobic strains in the multispecies biofilms.
Statistical analysis
All experiments were performed in at least biological triplicate. Sta-
tistical analysis was performed in SPSS 24.0. First, normality of the data
was examined via the Shapiro-Wilk test. Normally distributed data were
then assessed by a two-tailed independent samples t-test or one-way
Table 3
Real-time PCR primers used for P. melaninogenica, V. parvula, and F. nucleatum.
Species name Oligonucleotide sequence Amplicon size (bp) E
Prevotella melaninogenica F: 5’ - CTTGCACTCTTTGGACGTCGAC - 30
R: 5’ - TTACTTCAAATCTGATGCCGTCATCG - 30
133 1.76
Veillonella parvula F: 5’ - ATCAACCTGCCCTTCAGA - 30
R: 5’ - AAGCTCTGTTAATCGGGACG - 30
343 1.84
Fusobacterium nucleatum F: 5’ - CAAACGCGATAAGTAATC - 30
R: 5’ - CCCTTTCGTATGTTACCA - 30
273 1.94
E ¼ amplification efficiency. An efficiency of 2.00 is equivalent to 100% of theoretical amplification per PCR cycle.
E. Vandeplassche et al. Biofilm 2 (2020) 100031ANOVA followed by a Dunnett’s post hoc analysis. Not normally
distributed data were evaluated using a Mann-Whitney or Kruskal-Wallis
non-parametric test. Statistical significance of data is concluded when p-
values are 0.05.
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